Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Abbott Laboratories

Share:
Related ABT
Portfolio Managers Want You To Invest In 'Boring' Stocks In 2018, Here's Why
10 Technical Levels Discussed On Monday's PreMarket Prep
Dividend Income Update November 2017 (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Abbott Laboratories (NYSE: ABT), but lowered its price target from $87.00 to $39.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Abbott Laboratories closed on Tuesday at $33.36.

Latest Ratings for ABT

DateFirmActionFromTo
Oct 2017BarclaysMaintainsOverweight
Oct 2017CitigroupMaintainsNeutral
Oct 2017Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABT)

View Comments and Join the Discussion!

Partner Center